Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/145662
Title: Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials
Authors: Jang, Se Eun
Qiu, Lifeng
Chan, Ling Ling
Tan, Eng-King
Zeng, Li
Keywords: Science::Medicine
Issue Date: 2020
Source: Jang, S. E., Qiu, L., Chan, L. L., Tan, E.-K., & Zeng, L. (2020). Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials. Frontiers in Neuroscience, 14, 558532-. doi:10.3389/fnins.2020.558532
Journal: Frontiers in Neuroscience
Abstract: Curative therapies or treatments reversing the progression of Parkinson’s disease (PD) have attracted considerable interest in the last few decades. PD is characterized by the gradual loss of dopaminergic (DA) neurons and decreased striatal dopamine levels. Current challenges include optimizing neuroprotective strategies, developing personalized drug therapy, and minimizing side effects from the long-term prescription of pharmacological drugs used to relieve short-term motor symptoms. Transplantation of DA cells into PD patients’ brains to replace degenerated DA has the potential to change the treatment paradigm. Herein, we provide updates on current progress in stem cell-derived DA neuron transplantation as a therapeutic alternative for PD. We briefly highlight cell sources for transplantation and focus on cell assessment methods such as identification of genetic markers, single-cell sequencing, and imaging modalities used to access cell survival and function. More importantly, we summarize clinical reports of patients who have undergone cell-derived transplantation in PD to better perceive lessons that can be drawn from past and present clinical outcomes. Modifying factors include (1) source of the stem cells, (2) quality of the stem cells, (3) age of the patient, (4) stage of disease progression at the time of cell therapy, (5) surgical technique/practices, and (6) the use of immunosuppression. We await the outcomes of joint efforts in clinical trials around the world such as NYSTEM and CiRA to further guide us in the selection of the most suitable parameters for cell-based neurotransplantation in PD.
URI: https://hdl.handle.net/10356/145662
ISSN: 1662-4548
DOI: 10.3389/fnins.2020.558532
Rights: © 2020 Jang, Qiu, Chan, Tan and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
fnins-14-558532.pdf820.84 kBAdobe PDFView/Open

SCOPUSTM   
Citations 20

13
Updated on Dec 3, 2022

Web of ScienceTM
Citations 20

11
Updated on Nov 29, 2022

Page view(s)

113
Updated on Dec 5, 2022

Download(s) 50

63
Updated on Dec 5, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.